Cargando…

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Bjornstad, Petter, Laffel, Lori, Tamborlane, William V., Simons, Gudrun, Hantel, Stefan, von Eynatten, Maximilian, George, Jyothis, Marquard, Jan, Cherney, David Z.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	e-Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054503/ https://www.ncbi.nlm.nih.gov/pubmed/29941496 http://dx.doi.org/10.2337/dc18-0394

Ejemplares similares

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
por: Laffel, L. M. B., et al.
Publicado: (2018)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year
por: Sherr, Jennifer L., et al.
Publicado: (2016)

Improved estimation of glomerular filtration rate (GFR) by comparison of eGFR(cystatin C) and eGFR(creatinine)
por: Grubb, Anders, et al.
Publicado: (2012)

Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections
por: Foster, Nicole C., et al.
Publicado: (2016)

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
por: Sattar, Naveed, et al.
Publicado: (2018)

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
por: Ruggenenti, Piero, et al.
Publicado: (2021)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy
por: Perkins, Bruce A., et al.
Publicado: (2020)

OR31-06 Gender-Affirming Hormone Therapy Affects Serum Cystatin C-based eGFR In Transgender Individuals
por: van Eeghen, Sarah A, et al.
Publicado: (2023)

Treatable Diabetic Retinopathy Is Extremely Rare Among Pediatric T1D Exchange Clinic Registry Participants
por: Beauchamp, Giovanna, et al.
Publicado: (2016)

PCSK9 Is Increased in Youth With Type 1 Diabetes
por: Levenson, Amy E., et al.
Publicado: (2017)

Trends and Characteristics of Self-reported Case Presentation of Diabetes Diagnosis Among Youth From 2002 to 2010: Findings From the SEARCH for Diabetes in Youth Study
por: Saydah, Sharon H., et al.
Publicado: (2015)

Fasting Blood Glucose-A Missing Variable for GFR-Estimation in Type 1 Diabetes?
por: Bjornstad, Petter, et al.
Publicado: (2014)

Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
por: Cohen, Ricardo V., et al.
Publicado: (2021)

Lessons From Continuous Glucose Monitoring in Youth With Pre–Type 1 Diabetes, Obesity, and Cystic Fibrosis
por: Chan, Christine L., et al.
Publicado: (2020)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

Out of Pocket Diabetes-Related Medical Expenses for Adolescents and Young Adults With Type 1 Diabetes: The SEARCH for Diabetes in Youth Study
por: Merjaneh, Lina, et al.
Publicado: (2019)

Cystacin C-based eGFR and Creatinine Clearance-based eGFR in Patients with Severe Motor and Intellectual Disabilities
por: Tamura, Kouichi, et al.
Publicado: (2023)

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
por: Sridhar, Vikas S., et al.
Publicado: (2023)

The Effect of Cadmium on GFR Is Clarified by Normalization of Excretion Rates to Creatinine Clearance
por: Satarug, Soisungwan, et al.
Publicado: (2021)

Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR More than 30 ml/min/1.73m(2)
por: Nagata, Takanobu, et al.
Publicado: (2016)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications
por: Armstrong, Guy Philip
Publicado: (2020)

Point of Care eGFR and the Prediction of Outcomes in Pneumonia
por: Suk, Chi-won, et al.
Publicado: (2019)

Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care
por: Hirst, Jennifer A, et al.
Publicado: (2018)

Potential relationship between eGFR(cystatin C)/eGFR(creatinine)‐ratio and glomerular basement membrane thickness in diabetic kidney disease
por: Öberg, Carl M., et al.
Publicado: (2021)

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
por: Cherney, David Z.I., et al.
Publicado: (2022)

Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations
por: Eastwood, John B., et al.
Publicado: (2010)

International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE)
por: Caplin, Ben, et al.
Publicado: (2017)

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
por: Kahn, Steven, et al.
Publicado: (2019)

Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients
por: Costa, Ana Florencia, et al.
Publicado: (2019)

Short‐Term Change in eGFR and Risk of Cardiovascular Events
por: Turin, Tanvir Chowdhury, et al.
Publicado: (2014)

Age and the eGFR-dependent risk for adverse clinical outcomes
por: Liu, Ping, et al.
Publicado: (2022)

Performance of the race-free CKD-EPI creatinine-based eGFR equation in a Danish cohort with measured GFR
por: Munch, Philip Vestergaard, et al.
Publicado: (2023)

eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
por: Avotins, Lauris, et al.
Publicado: (2023)

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
por: Yasui, Atsutaka, et al.
Publicado: (2018)

Impaired selective renal filtration captured by eGFR(cysC)/eGFR(crea) ratio is associated with mortality in a population based cohort of older women
por: Malmgren, Linnea, et al.
Publicado: (2022)

The impact of automated eGFR reporting and education on nephrology service referrals
por: Noble, Euan, et al.
Publicado: (2008)

Renal quality outcomes framework and eGFR: impact on secondary care
por: Phillips, LA, et al.
Publicado: (2012)

Correlation analysis between eGFR(cys) and SXscore in patients with diabetes
por: YONG, ZHONG, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1nqtvocrs68j3ckg4ud6k2fjve